INTRODUCTION {#S5}
============

Pathogenic variants in *BRCA1* and *BRCA2* account for 20--25% of hereditary breast and ovarian cancer^[@R1]^, 5--10% of breast cancers^[@R2]^, and up to 15% of ovarian cancers^[@R3]^. While most known pathogenic variants in these genes truncate the encoded proteins, missense variants can also predispose to cancer. More than 90% of missense variants in public databases^[@R4]^ identified by clinical genetic testing are listed as variants of uncertain significance (VUS)^[@R5]^. Missense variants with definitive pathogenic or neutral status can inform clinical management, prevention, and treatment. Thus, accurate methods to establish variant pathogenicity are needed.

Family-based studies yielding likelihoods of pathogenicity, based on segregation of variants with cancer and personal and family history of cancer are established methods for determining pathogenicity of variants in *BRCA1* and *BRCA2*. However, few missense variants have been clinically annotated by this method owing to the limited availability of family-based data. Similarly, functional assays^[@R6],[@R7]^ with established specificity and sensitivity for known pathogenic and neutral *BRCA1* or *BRCA2* variants, have been used alone or in combination with family-based segregation data to infer pathogenicity^[@R8]^. However, classification of all possible variants by functional assays is unlikely. Alternatively, the clinical relevance of variants can be assessed using sequence-based *in silico* prediction models, which can be applied to all possible missense VUS in these genes. Given the large number of unique VUS identified in *BRCA1* and *BRCA2*, *in silico* prediction models will need to be incorporated in models that aim to predict the pathogenicity of VUS in these genes. Most commonly used prediction tools such as SIFT^[@R9]^, PolyPhen^[@R10]^, GERP^[@R11]^, Align-GVGD^[@R12]^, and CADD^[@R13]^ have been developed using large-scale databases such as the Human Gene Mutation Database (HGMD)^[@R14]^ or ClinVar^[@R4]^. While functional assays can out-perform these computational predictions of damage^[@R6],[@R15]^, development and/or calibration of *in silico* prediction models using well characterized functional data from validated assays is expected to improve variant annotation.

In this study, HDR^[@R6]^ functional data from 207 *BRCA2* variants and transcriptional integrity^[@R16],[@R17]^ data for 248 *BRCA1* variants were used to evaluate the performance of existing *in silico* algorithms. Sensitivity and specificity of the algorithms were optimized by defining more accurate thresholds, and by newer high performance Random Forest (RF) and naïve voting method (NVM) predictors. We show that optimization for one gene leads to poor performance when applied to the other, highlighting the importance of different gene-specific features for prediction accuracy.

MATERIALS AND METHODS {#S6}
=====================

BRCA1 transcription integrity assay {#S7}
-----------------------------------

Results from functional studies of variants in the BRCT domains of *BRCA1* using a transcription integrity assay have been reported previously^[@R16],[@R17]^. The sensitivity and specificity of this assay for missense variants in the BRCT domains of *BRCA1* have been estimated at 100% (Sensitivity, 95%CI: 75%−100%; Specificity, 95%CI: 83%−100%)^[@R16]^. The 95% probability of pathogenicity and neutrality from the VarCall two-component mixture model for classification of *BRCA1* missense variants^[@R8]^ was used to define 61 pathogenic, 21 indeterminate (partial effect on function), and 166 neutral variants (total of 248). These data were used to define *BRCA1* activity.

BRCA2 HDR assay {#S8}
---------------

A cell-based homology directed DNA repair activity assay was used to assess the influence of missense variants in the DNA binding domain of BRCA2 on protein activity^[@R6]^. In brief, BRCA2 activity in *brca2* deficient V-C8 cells expressing mutant forms of full-length BRCA2 was measured with a DR-GFP reporter plasmid after induction of a DNA double strand break using the I-Sce1 enzyme. The V-C8 hamster lung fibroblast cell line was a gift from Dr. Margaret Zdzienicka. Cells were verified by genotyping in the Mayo Clinic Medical Research Facility and routinely tested for mycoplasma contamination. The sensitivity and specificity of this assay for damaging missense variants in the DNA binding domain (DBD) of *BRCA2* has previously been estimated at 100% (Sensitivity, 95%CI: 79%−100%; Specificity, 95%CI: 93%−100%) using 21 known neutral and 13 known pathogenic variants^[@R6],[@R18]--[@R20]^. Results from 68 variants were combined with previous results from 139 previously characterized variants for a total of 207.

Damaging missense prediction tools {#S9}
----------------------------------

dbNSFP version 3.0a^[@R21]^ was downloaded and converted into a BioR catalogue^[@R22]^ to annotate variants. Align-GVGD^[@R12]^ was accessed online. CAROL and CONDEL scores were gathered from Variant Effect Predictor (VEP)^[@R23]^.

Optimized thresholds {#S10}
--------------------

Analyses included damaging, indeterminate, and neutral variants. Indeterminate variants were included in the neutral category (Scenario 1). An alternative approach, in which indeterminate variants are included in the pathogenic category (Scenario 2) is provided in Supplemental Materials. Optimal thresholds for individual predictive algorithms that maximized sensitivity and specificity for damaging variants were derived using results from the *BRCA1* transcriptional integrity assay and *BRCA2* HDR assay, individually ([Figure S1](#SD1){ref-type="supplementary-material"} and [S2](#SD2){ref-type="supplementary-material"}). Matthew's correlation coefficients (MCC) were calculated for each resulting binary classification relative to the functional assay standards^[@R24]^. The areas under the curve (AUCs) were estimated and reported with 95% confidence intervals using the DeLong error method. Receiver operating characteristic (ROC) analyses were performed using the package optimalCutpoints^[@R25]^ for R software (v3.3.3; [http://www.R-project.org](http://www.r-project.org/)).

### Naïve Voting Method (NVM) models. {#S11}

For each gene, a training set (a random sample of \~50% of the variants for each gene) and a test set (the remaining \~50%) were constructed using the *sample* function in R. The training set was used to determine the optimal number of individual prediction algorithms in the NVM model based on the maximal MCC. Starting with the individual prediction algorithm with the highest MCC, the prediction algorithm with the highest individual MCC among the models not previously chosen was added iteratively until the optimal numbers of prediction algorithms were included. If both a raw score (Score) and rank score (RankScore) for an algorithm were available, then only the RankScore was utilized. The NVM models and thresholds developed in the training sets were validated in the test sets. The MCC and other performance statistics were also re-calculated across the entire data sets (training and test combined) to be consistent with reporting of other models. Lollipop plots were generated with *lollipops* (v1.2, <http://dx.doi.org/10.5281/zenodo.46184>).

### Random Forest models. {#S12}

Random forest (RF) modelling utilized scores from each of the optimized individual prediction algorithms to identify the subset of prediction algorithms that maximized the accuracy of predicting damaging and non-damaging (indeterminate and neutral) variants in *BRCA1* and *BRCA2*. The randomForest R package^[@R26]^ was used with settings of n=500 trees and the number of predictor variables sampled as candidates at each split set to the recommended default of sqrt(*p*), where *p* is the number of predictor variables included in the model. For individual prediction algorithms available as both a Score and RankScore, only the RankScore was included in the random forest models. Variable importance was assessed using the mean decrease in accuracy resulting from exclusion of a given prediction model from the RF classifiers. Out-of-sample predictions on the probability scale were again derived for each model and used to estimate AUC, sensitivity, specificity, and MCC at optimized cut points for prediction of functional status.

Comparison to ClinVar {#S13}
---------------------

*BRCA1* and *BRCA2* classifications from ClinVar that were reviewed by an expert panel and had no conflicting interpretations were used. Pathogenic and likely pathogenic variants in ClinVar were grouped into the pathogenic (damaging) category, and variants annotated as benign or likely benign in ClinVar with no conflicting interpretations were defined as neutral (neutral).

Code availability {#S14}
-----------------

All code and data required to replicate all analyses are available on GitHub (<https://github.com/Steven-N-Hart/NVM>).

RESULTS {#S15}
=======

Functional characterization of 68 novel BRCA2 missense variants {#S16}
---------------------------------------------------------------

In this study, 68 *BRCA2* variants from the BRCA2 DBD were evaluated using the HDR assay. Of these, 17 showed HDR fold change \<1.66, with probabilities of pathogenicity \>0.99 ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}, [Table S1](#SD6){ref-type="supplementary-material"}), and 48 variants showed HDR\>2.41 and probabilities of neutrality \>0.99. Another three variants (p.I2672T, p.D2733V and p.P3150L) displayed partial activity (HDR fold change \>1.66 and \<2.41) and were annotated as indeterminate variants ([Figure 1](#F1){ref-type="fig"}, [Table S1](#SD6){ref-type="supplementary-material"}). When combined with previously classified variants^[@R6],[@R27]^, 69 were predicted deleterious (damaging), 21 were intermediate/partial (indeterminate), and 117 were predicted benign/neutral (neutral) ([Table 1](#T1){ref-type="table"}, [Table S1](#SD6){ref-type="supplementary-material"}).

Computational Predictions {#S17}
-------------------------

Sensitivity and specificity of 40 computational prediction models with previously established cut points for damaging variants were determined using the functional assay data for *BRCA1* and *BRCA2* missense variants ([Tables S2](#SD7){ref-type="supplementary-material"}, [Table S3](#SD6){ref-type="supplementary-material"}). These default thresholds yielded either high sensitivity with low specificity (e.g. *BRCA2* SIFT Score: sensitivity 100%, specificity \<20%) or low sensitivity with high specificity (e.g. *BRCA1* PROVEAN Score: sensitivity \<0.02%, specificity 100%), depending on the gene ([Table S3](#SD6){ref-type="supplementary-material"}).

To optimize the predictive ability of each model, thresholds that maximized sensitivity and specificity for damaging variants were defined separately for *BRCA1* and *BRCA2*. For the purposes of predicting damaging, clinically relevant variants, models were generated by combining indeterminate with neutral variants (Scenario 1). Performance characteristics and AUC values for optimized individual prediction models for *BRCA1* and *BRCA2* are shown in [Table 2](#T2){ref-type="table"} and [Figure S2](#SD2){ref-type="supplementary-material"}. The best performing individual models for *BRCA1* incorporated conservation measures including deep interspecies protein alignments and physicochemical changes in amino acids (MetaSVM Score and RankScore^[@R21]^; PERCH and PERCH_noMAF^[@R28]^; Align-GVGD^[@R12]^; Polyphen2Hvar Score and RankScore^[@R10]^, and VEST3 Score and RankScore^[@R29]^). These models yielded AUCs\>0.87, sensitivity and specificity \>80%, and MCCs up to 0.68 (VEST3Score) ([Table 2](#T2){ref-type="table"}, [Table S4](#SD6){ref-type="supplementary-material"}). These results represented a major improvement in performance over results based on default thresholds (mean = 0.29) ([Table S3](#SD6){ref-type="supplementary-material"}). The best performing models for *BRCA2* were PERCH and PERCH_noMAF; MetaLR RankScore and Score; MetaSVM RankScore and Score; and VEST3 RankScore and Score. These yielded AUCs of 0.83--0.89, sensitivity and specificity \>78% (85% for PERCH), and MCCs\>0.53 ([Table 2](#T2){ref-type="table"}, [Table S4](#SD6){ref-type="supplementary-material"}), which were substantially improved over models using default parameters (MCC\<0.42) ([Table S3](#SD6){ref-type="supplementary-material"}).

To assess whether meta-predictor models improved prediction of the damaging variants for each gene, two new models were developed for both *BRCA1* and *BRCA2*: (1) Random Forest (RF) classifiers of prediction methods were derived from the continuous outputs from the functional data (BRCA1-RF and BRCA2-RF); (2) naïve voting methods (NVM) were applied to optimized thresholds for each prediction model (BRCA1-NVM and BRCA2-NVM). CAROL^[@R30]^ and CONDEL^[@R31]^ predictors were not included in development of new *BRCA2* models because prediction scores for 29 of 207 (14.0%) variants were not available. Only 12 of 248 (4.8%) *BRCA1* and 1 of 207 (0.5%) *BRCA2* variants were excluded from new model development due to missing data or conflicts between protein and DNA sequences ([Table S2](#SD7){ref-type="supplementary-material"}).

RF-Models {#S18}
---------

Random Forest (RF) classifiers were used to evaluate the impact of excluding individual prediction methods on the accuracy of composite prediction models. VEST3 RankScore and Align-GVGD had the greatest impact on the accuracy of BRCA1-RF, whereas Mutation Assessor RankScore and PERCH had the greatest impact on BRCA2-RF. The BRCA1-RF model (threshold ≥0.298) ([Table S4](#SD6){ref-type="supplementary-material"}) showed the second highest AUC value of all models for *BRCA1* (0.92, 95%CI:0.88--0.96), with 86% sensitivity and 85% specificity. The BRCA1-RF model predicted 8 of 59 (13.6%) functionally impaired *BRCA1* variants as neutral (false negatives), 12 of 21 (57.1%) functionally indeterminate variants as damaging, and 14 of 156 (9.0%) functionally intact neutral variants as damaging (false positives) ([Table S2](#SD7){ref-type="supplementary-material"}). Similarly, the BRCA2-RF model (threshold ≥0.371) ([Table S4](#SD6){ref-type="supplementary-material"}) had the highest AUC for *BRCA2* (0.90, 95%CI:0.84--0.95) ([Table 2](#T2){ref-type="table"}, [Table S4](#SD6){ref-type="supplementary-material"}) with 83% sensitivity and 82% specificity ([Table S4](#SD6){ref-type="supplementary-material"}, [Figure 2](#F2){ref-type="fig"}).

NVM-Models {#S19}
----------

NVM models based on the optimal number of individual prediction algorithms for *BRCA1* and *BRCA2* variants were also developed. The optimal NVM for *BRCA1*, following training and validation (BRCA1-NVM Combined) contained 13 prediction models ([Table S5](#SD6){ref-type="supplementary-material"}). *BRCA1* variants are predicted damaging when ≥9 of the 13 models exceed their individual thresholds for damaging variants ([Table S5](#SD6){ref-type="supplementary-material"}). BRCA1-NVM yielded an AUC of 0.94 with sensitivity of 83% and specificity of 91%. The highest proportion of *BRCA1* misclassifications involved variants with indeterminate function, with 9 of 21 (42.9%) annotated as damaging. In contrast, the optimal BRCA2-NVM (BRCA2-NVM Combined) model after training and validation incorporated six prediction models with a threshold of ≥4 models predicting damaging variants ([Table S5](#SD6){ref-type="supplementary-material"}). This model yielded sensitivity of 82% and specificity of 87% ([Table 2](#T2){ref-type="table"}, [Table S4](#SD6){ref-type="supplementary-material"}, [Table S5](#SD6){ref-type="supplementary-material"}), with 14 functionally damaging variants predicted as neutral, and 18 indeterminate/neutral variants predicted as damaging. As with *BRCA1*, the false positive results were disproportionately enriched for indeterminate function with 6 of 21 (28.6%) misclassified. Overall, the predictive abilities of the RF and NVM models showed substantial improvement over individual *in silico* prediction methods using default parameters, and modest improvements over the best performing individual *in silico* methods optimized at thresholds specific to *BRCA1* and *BRCA2*.

Application of selected models to all possible missense variants in BRCA1 and BRCA2 {#S20}
-----------------------------------------------------------------------------------

The RF and NVM models were used to assess the damaging potential of all theoretically possible missense substitutions resulting from single nucleotide changes in *BRCA1* and *BRCA2*, contingent on availability of prediction scores from all the individual methods contributing to each model ([Table S2](#SD7){ref-type="supplementary-material"}). Because a subset of the contributing prediction algorithms are in part based on nucleotide substitution rates, several missense variants caused by different nucleotide changes may have more than one predicted RF or NVM score. Using BRCA1*-*NVM, 7.1% of *BRCA1* variants were predicted as damaging. Similarly, 2.6% of *BRCA2* variants were predicted as damaging using BRCA2-NVM. However, marked enrichment for NVM predicted damaging variants was observed in known functional domains ([Figure 3](#F3){ref-type="fig"}). Analysis of the *BRCA1* RING domain, predicted that 30--40% of all missense changes disrupt protein function. Similarly, 46% of all possible missense variants in the C-terminal BRCT domains and \>20% in the larger C-terminal region (residue 1660--1810) were predicted damaging ([Table S2](#SD7){ref-type="supplementary-material"}). Interestingly, \~10% of all possible variants between amino acids 300 to 550, which have been associated with TP53^[@R32]^, RAD50^[@R33]^, and c-MYC^[@R32]^ interactions, were predicted damaging ([Table S2](#SD7){ref-type="supplementary-material"}). For *BRCA2*, only the region from residues 2574 to 2771 that contains the helical and OB1 domains of the DNA binding domain was predicted to have \>20% damaging variants, although 10% of variants in OB3 were also predicted damaging ([Figure 3](#F3){ref-type="fig"}, [Table S2](#SD7){ref-type="supplementary-material"}). Few damaging missense variants were predicted in the OB2 domain. Similar results were obtained using the RF model ([Table S2](#SD7){ref-type="supplementary-material"}). Damaging mutations were not predicted in the N-terminus of *BRCA2*, containing the PALB2 interaction domain^[@R34]^, possibly because of the small size of the interaction site.

DISCUSSION {#S21}
==========

Specific measures of *BRCA1* and *BRCA2* functional activity have been established as reliable measures of the functional impact and the likelihood of pathogenicity of variants in certain domains of *BRCA1* and *BRCA2*^[@R6],[@R16]^. However, in the absence of functional studies of individual variants, *in silico* models that incorporate functional or structural data are often considered useful predictors of function. Here, existing models for prediction of damaging missense variants were recalibrated based on *BRCA1* and *BRCA2* functional data and were combined in meta-predictor classifiers (NVM and RF). These meta-predictors leveraged the strengths and weaknesses and improved upon many of the individual models for predicting the functional implications of missense variants in the cancer risk-associated domains of *BRCA1* and *BRCA2*. We subsequently used these highly sensitive and specific models to annotate all missense variants from the *BRCA1* and *BRCA2* genes as damaging or neutral. Importantly, because the *BRCA1* transcriptional integrity assay and the *BRCA2* HDR assay used for calibration of the various prediction models have 100% sensitivity and specificity for clinically pathogenic variants in the *BRCA1* BRCT and *BRCA2* DNA binding domain domains, respectively, the models may also predict the clinical pathogenicity of missense variants in these domains. Whether prediction of functional effects in other parts of these proteins also reflects pathogenicity remains to be determined using additional pathogenic and neutral standards. Overall, these prediction models are likely to alter the interpretation of many VUS in *BRCA1* and *BRCA2*, leading to improved clinical genetic testing, and perhaps improved risk management of patients found to carry VUS.

The current American College of Medical Genetics guidelines for variant classification recommends that *in silico* evidence can be counted as supporting evidence for pathogenicity (or lack thereof) if all of the *in silico* programs tested agree on the prediction, whereas *in silico* evidence should not be used for classification if *in silico* predictions disagree. However, the guidelines do not recommend specific *in silico* methods, or indicate the number of methods that should be evaluated^[@R35]^. This differs from the NVM model in two key areas. First, default thresholds of predictive models are not appropriate for *BRCA1* and *BRCA2* because the specificity is very low. The new thresholds for predictive models derived here should provide more accurate predictions of functional impact and therefore pathogenicity. Second, while using an ensemble of models is a rational strategy, requiring all models to be in agreement becomes overly stringent resulting in decreased performance ([Figure S3](#SD3){ref-type="supplementary-material"} and [Figure S4](#SD4){ref-type="supplementary-material"}). Rather, the number of *in silico* models, the choice of which specific models, and the thresholds for those models that are required for an accurate consensus with both high sensitivity and specificity can vary by gene.

Effect of grouping indeterminate variants as either damaging or neutral {#S22}
-----------------------------------------------------------------------

Generally, the performance of individual *in silico* prediction models, as well as the RF and NVM, were similar when indeterminate variants were grouped with either damaging or neutral. However, the performance of some of the known prediction methods was highly sensitive to indeterminate variant classification. Interestingly, the prediction methods that had the greatest difference in thresholds, depending on the incorporation of the indeterminate variants in the damaging or neutral categories, also had higher AUCs (e.g. PERCH, NVM, RF, MetaSVM) compared to those with no change in threshold (e.g. PolyPhen2HDiv, PolyPhen2HVar, MutationTaster Score), suggesting that the former methods are better predictors of indeterminate impact on function. However, the clinical relevance of the indeterminate variants in *BRCA1* and *BRCA2* is not well understood. Further understanding of function, pathogenicity, cancer risk, and associated refinement of thresholds for damage and pathogenicity for each functional assay may allow recalibration of the prediction models and improved prediction of clinically relevant *BRCA1* and *BRCA2* variants in the future.

Extending missense prediction outside established functional domains {#S23}
--------------------------------------------------------------------

When cross-referencing the NVM predictions with well-annotated ClinVar classifications, the predictions clustered in well-known domains, with damaging missense variants mostly restricted to BRCT and RING domains of *BRCA1* and the DNA binding domain of *BRCA2* ^[@R12]^ ([Figure S5](#SD5){ref-type="supplementary-material"}). The BRCA1-NVM prediction model clearly delineated both regions, with as many as 40% of missense variants in the RING domain and 50% in parts of the BRCT regions annotated as damaging. Interestingly, enrichment between amino acids 400--500 was also observed, but no damaging variants in this region have been defined by functional studies and no pathogenic variants have yet been observed in the clinically tested population. According to the BRCA1-NVM model, the total proportion of all theoretically possible damaging variants in *BRCA1* is \~8%, almost all of which are located in the known RING and BRCT domains. For *BRCA2*, family based studies in combination with the Align-GVGD prediction method were previously used to estimate that 33% of missense variants in the *BRCA2* DNA binding domain were damaging^[@R36]^. While based on small numbers of missense variants, this is consistent with predictions from the NVM and RF models for *BRCA2*, although the frequency based on the BRCA2-NVM and BRCA2-RF models is as high as 50% in specific regions. A notable drop in the estimated pathogenic potential was observed in the *BRCA2* OB2 DNA binding domain. This was also observed when considering all pathogenic *BRCA2* missense mutations listed in ClinVar.

However, it should be noted that when applied to genes other than *BRCA1* and *BRCA2* ([Table S6](#SD8){ref-type="supplementary-material"}) (or even BRCA1-RF or -NVM and applied to *BRCA2* and vice versa), the performance of the NVM and RF models was much lower, with MCCs \<0.40, as shown for the BRCA2-NVM ([Table S7](#SD6){ref-type="supplementary-material"}). The sizable reduction in model accuracy suggested that recalibrated models are specific to the initial gene of interest and cannot be effectively extrapolated to other disease genes. Another potential explanation for this phenomenon is that not all missense variants in other genes may exert phenotypic effects through loss of activity. Because the *BRCA1* and *BRCA2* assays are limited to measurement of loss of function, perhaps more comprehensive assays to evaluate splicing alterations, gain-of-function mutations, and epigenetic influences on gene function are needed in order to extend the NVM and RF prediction models to other genes. Separately, disruption of functions other than transcriptional activation or homology directed repair by missense variants could result in recalibration of the NVM and RF prediction models. Other influences on model performance may include AT versus GC content of coding sequences and codon usage, and the structural effects of observed variants. Finally, the differences could be due to evolutionary constraint -- since some models like Align GVGD and PolyPhen2 perform well for the highly conserved *BRCA1*, but profoundly less so for the less constrained *BRCA2*.

While the clinical implications of truncating mutations in the *BRCA1* and *BRCA2* breast cancer predisposition genes are clear, interpretation of missense variants is more challenging. Here we present an approach for predicting the functional impact and potentially the pathogenicity of missense *BRCA1* and *BRCA2* variants, based on functional evaluation of variants and *in silico* sequence-based analysis. The functional studies of *BRCA2* variants in combination with similar studies of *BRCA1* now identify 130 variants in these genes that are damaging and likely pathogenic and may substantially increase risk of breast, ovarian, and other cancers. In contrast, public databases currently identify fewer than 40 such variants. In the absence of functional results, other methods for variant assessment are needed. Many *in silico* prediction methods exist for characterization of missense variants, but the interpretation of results from these methods, and the accuracy of the methods for predicting whether variants in *BRCA1* and *BRCA2* are damaging or neutral are not well defined. Here we recalibrated established *in silico* prediction methods for missense variants using results from *BRCA1* and *BRCA2* functional assays and developed RF and NVM models that incorporate multiple *in silico* prediction methods. These classifiers out-performed the individual *in silico* models. Overall this approach leverages measures of *BRCA1* and *BRCA2* functional activity to improve the classification of *BRCA1* and *BRCA2* VUS detected by clinical genetic testing and tumor sequencing.
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======================

FUNDING

This work was supported by the Breast Cancer Research Foundation; National Institutes of Health grants \[CA192393, CA176785, CA116167\]; and a National Cancer Institute Specialized Program of Research Excellence (SPORE) in Breast Cancer to Mayo Clinic \[P50 CA116201\].

CONFLICT OF INTEREST

The authors have no relevant conflicts of interest.

![HDR activity of 207 *BRCA2* missense variants.\
The model-based HDR fold change with standard error (SE) is displayed on a logarithmic scale. The SE is included as a measure of the reproducibility of the HDR assay for each variant. Solid lines represent 99% probability of pathogenicity and 99% probability of neutrality (fold increase in GFP (+) cells \< 1.66 for damaging and fold increase in GFP (+) cells \> 2.41 for neutral). Dotted lines separate variants classified as deleterious, indeterminate, and neutral.](nihms-953431-f0001){#F1}

![Matthews Correlation Coefficients (MCC) for 42 *in silico* predictors with optimized thresholds for damaging versus indeterminate/neutral variants in *BRCA1* and *BRCA2*.\
Higher values indicate increased classifier performance.](nihms-953431-f0002){#F2}

![Estimates of the proportion of damaging missense variants by position in each gene.\
The AAPOS x-axis represents the amino acid position, and the y-axis is the probability of a missense mutation being damaging from the NVM model. The lines were smoothed using a 50 amino acid sliding window.](nihms-953431-f0003){#F3}

###### 

Predicted pathogenic missense variants defined by the BRCA2 HDR assay

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variant   cDNA         AGVGD\   IARC\     FC[\*](#TFN1){ref-type="table-fn"}   SE^[\#](#TFN2){ref-type="table-fn"}^   p\                p\             Origin
                         class    class                                                                                 (pathogenicity)   (neutrality)   
  --------- ------------ -------- --------- ------------------------------------ -------------------------------------- ----------------- -------------- -----------------------
                                                                                                                                                         

  G2748D    c.8243G\>A   C65      Class 5   0.68                                 ± 0.07                                 1.00              2.96E-12       Lindor et al., 2012

  L2686P    c.8057T\>C   C45                0.72                                 ± 0.04                                 1.00              9.50E-12       Guidugli et al., 2017

  L2653P    c.7958T\>C   C65      Class 5   0.75                                 ± 0.08                                 1.00              3.40E-11       Lindor et al., 2012

  E2663K    c.7987G\>A   C55                0.83                                 ± 0.01                                 1.00              4.00E-10       Current study

  R3052W    c.9154C\>T   C65      Class 5   0.86                                 ± 0.09                                 1.00              9.33E-10       Lindor et al., 2012

  L2721H    c.8162T\>A   C25                0.88                                 ± 0.10                                 1.00              1.70E-09       Guidugli et al., 2017

  Y2624D    c.7870T\>G   C65                0.88                                 ± 0.06                                 1.00              1.75E-09       Current study

  Y2624H    c.7870T\>C   C65                0.89                                 ± 0.31                                 1.00              2.40E-09       Current study

  L3125R    c.9374T\>G   C65                0.91                                 ± 0.00                                 1.00              3.41E-09       Current study

  R2784W    c.8350C\>T   C65                0.91                                 ± 0.10                                 1.00              3.88E-09       Guidugli et al., 2017

  A2603P    c.7807G\>C   C25                0.92                                 ± 0.60                                 1.00              4.78E-09       Guidugli et al., 2017

  N3124I    c.9371A\>T   C65      Class 4   0.92                                 ± 0.10                                 1.00              4.65E-09       Guidugli et al., 2013

  L2647P    c.7940T\>C   C65      Class 4   0.93                                 ± 0.10                                 1.00              5.79E-09       Lindor et al., 2012

  S2670L    c.8009C\>T   C15                0.93                                 ± 0.07                                 1.00              6.20E-09       Guidugli et al., 2017

  G3076E    c.9227G\>A   C65                0.95                                 ± 0.10                                 1.00              1.02E-08       Guidugli et al., 2017

  Y2624N    c.7870T\>A   C65                0.95                                 ± 0.00                                 1.00              1.20E-08       Current study

  L3125H    c.9374T\>A   C65                0.96                                 ± 0.07                                 1.00              1.36E-08       Guidugli et al., 2017

  L2510P    c.7529T\>C   C65                0.98                                 ± 0.11                                 1.00              2.61E-08       Guidugli et al., 2017

  K2630Q    c.7888A\>C   C45                0.98                                 ± 0.08                                 1.00              2.49E-08       Guidugli et al., 2017

  R2824G    c.8470A\>G   C65                1.00                                 ± 0.20                                 1.00              3.72E-08       Current study

  H2623R    c.7868A\>G   C25                1.00                                 ± 0.04                                 1.00              3.59E-08       Guidugli et al., 2017

  D2723H    c.8167G\>C   C65      Class 5   1.00                                 ± 0.01                                 1.00              3.81E-08       Lindor et al., 2012

  N2781I    c.8342A\>T   C65                1.00                                 ± 0.10                                 1.00              4.08E-08       Current study

  I2627F    c.7879A\>T   C15      Class 5   1.01                                 ± 0.08                                 1.00              4.83E-08       Lindor et al., 2012

  A2730P    c.8188G\>C   C0                 1.01                                 ± 0.01                                 1.00              5.46E-08       Current study

  L2688P    c.8063T\>C   C65      Class 4   1.02                                 ± 0.08                                 1.00              5.80E-08       Guidugli et al., 2013

  G3076R    c.9227G\>T   C65                1.03                                 ± 0.08                                 1.00              8.66E-08       Guidugli et al., 2017

  G3076V    c.9226G\>C   C65                1.03                                 ± 0.11                                 1.00              8.08E-08       Guidugli et al., 2017

  D2723V    c.8168A\>T   C65                1.04                                 ± 0.08                                 1.00              1.01E-07       Guidugli et al., 2017

  W2788R    c.8362T\>C   C25                1.05                                 ± 0.08                                 1.00              1.37E-07       Guidugli et al., 2017

  D2723A    c.8168A\>C   C65                1.06                                 ± 0.11                                 1.00              1.49E-07       Guidugli et al., 2017

  W2788S    c.8363G\>C   C35                1.06                                 ± 0.08                                 1.00              1.44E-07       Guidugli et al., 2017

  N3124K    c.9372C\>A   C65                1.07                                 ± 0.06                                 1.00              1.89E-07       Current study

  G2609V    c.7826G\>T   C65                1.07                                 ± 0.08                                 1.00              2.24E-07       Guidugli et al., 2017

  F2642S    c.7925T\>C   C45                1.07                                 ± 0.08                                 1.00              2.02E-07       Guidugli et al., 2017

  D3095E    c.9285C\>G   C35      Class 4   1.07                                 ± 0.12                                 1.00              1.89E-07       Guidugli et al., 2013

  T2722R    c.8165C\>G   C65      Class 5   1.08                                 ± 0.08                                 1.00              2.78E-07       Lindor et al., 2012

  G2508R    c.7522G\>C   C65                1.09                                 ± 0.15                                 1.00              2.92E-07       Current study

  S2691F    c.8072C\>T   C0                 1.10                                 ± 0.06                                 1.00              4.09E-07       Guidugli et al., 2017

  E3002K    c.9004G\>A   C55                1.10                                 ± 0.08                                 1.00              4.35E-07       Guidugli et al., 2017

  D2723G    c.8168A\>G   C65      Class 5   1.11                                 ± 0.12                                 1.00              5.19E-07       Lindor et al., 2012

  W2626R    c.7876T\>C   C65                1.12                                 ± 0.01                                 1.00              6.04E-07       Current study

  G2596E    c.7787G\>A   C65                1.12                                 ± 0.09                                 1.00              5.77E-07       Guidugli et al., 2017

  Q2561P    c.7682A\>C   C15                1.13                                 ± 0.06                                 1.00              7.81E-07       Guidugli et al., 2017

  V2687F    c.8059G\>T   C0                 1.14                                 ± 0.02                                 1.00              8.96E-07       Current study

  H2623Y    c.7867C\>T   C65                1.15                                 ± 0.01                                 1.00              1.32E-06       Current study

  W2626C    c.7878G\>C   C65      Class 5   1.16                                 ± 0.13                                 1.00              1.56E-06       Lindor et al., 2012

  G2793R    c.8377G\>A   C65                1.18                                 ± 0.09                                 1.00              2.23E-06       Guidugli et al., 2017

  A3028P    c.9082G\>C   C0                 1.18                                 ± 0.04                                 1.00              2.48E-06       Current study

  L2792P    c.8375T\>C   C65                1.19                                 ± 0.09                                 1.00              3.03E-06       Guidugli et al., 2017

  G2793E    c.8378G\>A   C65                1.19                                 ± 0.07                                 1.00              2.71E-06       Guidugli et al., 2017

  A2786P    c.8356G\>C   C0                 1.23                                 ± 0.09                                 1.00              5.97E-06       Guidugli et al., 2017

  R2784Q    c.8351G\>A   C35                1.27                                 ± 0.14                                 1.00              1.46E-05       Guidugli et al., 2017

  G2596R    c.7786G\>C   C65                1.28                                 ± 0.10                                 1.00              1.73E-05       Guidugli et al., 2017

  G2585R    c.7753G\>A   C65                1.30                                 ± 0.10                                 1.00              2.47E-05       Guidugli et al., 2017

  G3003E    c.9008G\>A   C65                1.33                                 ± 0.08                                 1.00              4.59E-05       Guidugli et al., 2017

  G2609D    c.7826G\>A   C65      Class 4   1.35                                 ± 0.07                                 1.00              6.19E-05       Guidugli et al., 2013

  W2725L    c.8174G\>T   C55                1.35                                 ± 0.10                                 1.00              6.73E-05       Guidugli et al., 2017

  K2498E    c.7492A\>G   C55                1.36                                 ± 0.10                                 1.00              7.98E-05       Guidugli et al., 2017

  Q2655R    c.7964A\>G   C35                1.38                                 ± 0.09                                 1.00              1.13E-04       Guidugli et al., 2017

  Y2726C    c.8177A\>G   C65                1.49                                 ± 0.16                                 1.00              7.86E-04       Guidugli et al., 2017

  Q2925K    c.8773C\>A   C45                1.51                                 ± 0.12                                 1.00              1.07E-03       Guidugli et al., 2017

  D3073G    c.9218A\>G   C65                1.52                                 ± 0.12                                 1.00              1.17E-03       Guidugli et al., 2017

  R2659G    c.7975A\>G   C65                1.57                                 ± 0.12                                 1.00              2.57E-03       Guidugli et al., 2017

  Y2624C    c.7871A\>G   C65                1.57                                 ± 0.05                                 1.00              2.71E-03       Current study

  R2842P    c.8525G\>C   C65                1.59                                 ± 0.05                                 1.00              3.40E-03       Current study

  D2611G    c.7832A\>G   C65                1.61                                 ± 0.12                                 0.99              5.09E-03       Guidugli et al., 2017

  Y2660D    c.7978T\>G   C65                1.61                                 ± 0.12                                 0.99              5.03E-03       Guidugli et al., 2017

  N2622S    c.7865A\>G   C45                1.63                                 ± 0.13                                 0.99              6.76E-03       Current study
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fold Change in GFP positive cells in HDR assay;

Standard Error

###### 

Performance of *in silico* prediction models with optimized thresholds for classification of BRCA1 and BRCA2 missense variants

  -----------------------------------------------------------------------------------------------------------------
  Gene                     Model            Optimal\              AUC (95%CI)           FN / FP / TP / TN   MCC
                                            Threshold                                                       
  ------------------------ ---------------- --------------------- --------------------- ------------------- -------
                                                                                                            

   BRCA1                   NVM-Validation   ≥9                    0.94 (0.897--0.983)   5 / 8 / 25 / 79     0.719

  Vest3RankScore           ≥0.85546         0.9 (0.849--0.95)     8 / 24 / 51 / 153     0.678               

  Vest3Score               ≥0.868           0.9 (0.849--0.95)     8 / 24 / 51 / 153     0.678               

  RF                       ≥0.298           0.92 (0.879--0.96)    8 / 26 / 51 / 151     0.663               

  AlignGVGDPrior           ≥0.29            0.88 (0.829--0.931)   7 / 37 / 54 / 150     0.614               

  PERCHnoMAF               ≥0.206316        0.87 (0.814--0.924)   10 / 31 / 51 / 156    0.614               

  PERCH                    ≥0.239853        0.87 (0.819--0.922)   10 / 32 / 51 / 155    0.607               

  Polyphen2HvarRankScore   ≥0.91584         0.89 (0.845--0.93)    11 / 30 / 48 / 147    0.593               

  Polyphen2HvarScore       ≥0.999           0.89 (0.845--0.93)    11 / 30 / 48 / 147    0.593               

  MetaSVMRankScore         ≥0.9083          0.89 (0.844--0.928)   11 / 34 / 48 / 143    0.565               

                                                                                                            

  BRCA2                    NVM-Validation   ≥4                    0.89 (0.826--0.963)   6 / 9 / 29 / 59     0.683

  PERCH                    ≥0.295957        0.89 (0.847--0.939)   11 / 21 / 60 / 115    0.672               

  PERCHnoMAF               ≥0.272149        0.88 (0.832--0.929)   12 / 23 / 59 / 113    0.642               

  RFModel                  ≥0.371           0.9 (0.843--0.947)    12 / 24 / 59 / 111    0.633               

  MetaSVMRankScore         ≥0.93181         0.87 (0.824--0.923)   15 / 29 / 56 / 107    0.555               

  MetaSVMScore             ≥0.7002          0.87 (0.824--0.923)   15 / 29 / 56 / 107    0.555               

  MetaLRRankScore          ≥0.92107         0.87 (0.823--0.922)   16 / 30 / 55 / 106    0.535               

  MetaLRScore              ≥0.7679          0.87 (0.823--0.922)   16 / 30 / 55 / 106    0.535               

  Vest3RankScore           ≥0.79963         0.83 (0.776--0.893)   16 / 30 / 55 / 106    0.535               

  Vest3Score               ≥0.811           0.83 (0.776--0.893)   16 / 30 / 55 / 106    0.535               
  -----------------------------------------------------------------------------------------------------------------

FN: False negative; FP: False positive; TP: True positive; TN: True negative

AUC: Area under the curve from Receiver Operator characteristic analysis

MCC: Matthew Correlation Coefficient
